The rationale for this combination is that DDR inhibitors can increase tumor immunogenicity by promoting accumulation of DNA damage, leading to the presence of cytosolic DNA fragments that activate the cGAS-STING pathway. This evidence concerns the gene STING1 and neoplasm.